A rapid communication published on April 12th 2012 describes the early results of the annual multicentre case-control study undertaken by the ECDC sponsored I-MOVE consortium whose work is coordinated by an Epiconcept team
Preliminary results of European vaccine effectiveness study show decreased protective effect of the seasonal influenza vaccine in 2011/2012 season. ECDC Director Marc Sprenger calls for action.
In the autumn of 2011 a United States Government body, the NSABB established under the National Institutes of Health considered two scientific papers describing experimental work manipulating avian influenza viruses.
ECDC and the European Respiratory Society (ERS) have developed 21 patient-centred standards that aim to guide clinicians and public health workers in their daily work to ensure optimal diagnosis, treatment and prevention of tuberculosis (TB) in Europe. Nearly 74 000 reported TB cases in the EU/EEA in 2010 clearly show that tuberculosis remains a public health challenge across the region.
A pair of linked papers from Finland concerning the above topic, one epidemiological and the second combining both clinical and epidemiological were published on March 28th in the open access journal, PLoS One.(1,2).
In a hearing at the European Parliament in Brussels, ECDC Director Marc Sprenger underlined the importance of sufficient resources at national level to diagnose and adequately treat tuberculosis.
This workshop enabled all to agree on the relevance of EPIS VPD to be used as a platform for the reporting and monitoring of measles outbreak in the EU, agree on the type of information to be reported, the nature of outbreaks to be notified and the further usage by ECDC (e.g. European Monthly Measles Monitoring1) and other Member States of data that will be shared through EPIS VPD by countries.